Cerca
image du produit
The Journal of Prevention of Alzheimer's Disease

Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project - 21/11/24

Doi : 10.14283/jpad.2024.32 
K. Malzbender 1, P. Barbarino 2, P. Barkman Ferrell 3, A. Bradshaw 4, A.J. Brookes 5, C. Díaz 6, W.M. van der Flier 7, 8, 9, J. Georges 4, O. Hansson 10, 11, M. Hartmanis 12, L. Jönsson 13, R. Krishnan 34, T. MacLeod 3, F. Mangialasche 13, 14, P. Mecocci 13, 15, C. Minguillon 16, 17, 18, L. Middleton 19, 20, S. Pla 6, S.P. Sardi 34, M. Schöll 21, 22, 23, M. Suárez-Calvet 16, 17, 18, 24, W. Weidner 2, P.J. Visser 7, 13, 25, H. Zetterberg 26, 27, 28, 29, 30, 31, N. Bose 1, A. Solomon 13, 19, 32, Miia Kivipelto 12, 13, 14, 19, 33, 35, ⁎

AD-RIDDLE Consortium

1 Health and Life Sciences, Gates Ventures, Kirkland, WA, USA 
2 Alzheimer’s Disease International, London, UK 
3 Davos Alzheimer Collaborative, Geneva, Switzerland 
4 Alzheimer Europe, Luxembourg Ville, Luxembourg 
5 Department of Genetics and Genome Biology, University of Leicester, Leicester, UK 
6 Synapse Research Management Partners SL, Madrid, Spain 
7 Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands 
8 Neurodegeneration, Amsterdam Neuroscience, Amsterdam, Netherlands 
9 Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands 
10 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden 
11 Memory Clinic, Skåne University Hospital, Malmö, Sweden 
12 FINGERS Brain Health Institute, Stockholm, Sweden 
13 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden 
14 Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden 
15 Department of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy 
16 Pasqual Maragall Foundation, Barcelonapeta Brain Research Center (BBRC), Barcelona, Spain 
17 Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain 
18 Centro de Investigación Biomídica en Red de Fragilidad y Envejecimiento Saludable (CIBER-FES), Instituto de Salud Carlos III, Madrid, Spain 
19 Ageing Research, School of Public Health, Imperial College London, London, UK 
20 Directorate of Public Health and Primary Care, Imperial College NHS Healthcare Trust, London, UK 
21 Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden 
22 Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK 
23 Department of Psychiatry, Cognition and Aging Psychiatry, Sahlgrenska University Hospital, Mölndal, Sweden 
24 Servei de Neurologia, Hospital del Mar, Barcelona, Spain 
25 Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands 
26 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden 
27 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 
28 Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK 
29 UK Dementia Research Institute at UCL, London, UK 
30 Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China 
31 Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 
32 Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland 
33 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland 
34 Rare and Neurologic Diseases Research, Sanofi Research and Development, Cambridge, MA, USA 
35 Center for Alzheimer’s Research, Karolinska Universitetssjukhuset, Karolinska Vagen 37 A, QA32, 171 64, Solna, Sweden 

ad miia.kivipelto@ki.se miia.kivipelto@ki.se
connettersi o creare un account

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

The Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement (AD-RIDDLE) project, recently launched with the support of the EU Innovative Health Initiative (IHI) public-private partnership and UK Research and Innovation (UKRI), aims to develop, test, and deploy a modular toolbox platform that can reduce existing barriers to the timely detection, and therapeutic approaches in Alzheimer’s disease (AD), thus accelerating AD innovation. By focusing on health system and health worker practices, AD-RIDDLE seeks to improve and smooth AD management at and between each key step of the clinical pathway and across the disease continuum, from at-risk asymptomatic stages to early symptomatic ones. This includes innovation and improvement in AD awareness, risk reduction and prevention, detection, diagnosis, and intervention. The 24 partners in the AD-RIDDLE interdisciplinary consortium will develop and test the AD-RIDDLE toolbox platform and its components individually and in combination in six European countries. Expected results from this cross-sectoral research collaboration include tools for earlier detection and accurate diagnosis; validated, novel digital cognitive and blood-based biomarkers; and improved access to individualized preventative interventions (including multimodal interventions and symptomatic/disease-modifying therapies) across diverse populations, within the framework of precision medicine. Overall, AD-RIDDLE toolbox platform will advance management of AD, improving outcomes for patients and their families, and reducing costs.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Alzheimer’s disease, dementia, biomarkers, precision medicine, implementation, real world data


Mappa


 AD-RIDDLE Consortium Members: • Region Stockholm (Karolinska University Hospital); • Karolinska Institutet; • FINGERS Brain Health Institute; • Göteborgs Universitet; • Lund University; • University of Eastern Finland; • Stichting Amsterdam UMC; • Universiteit Maastricht; • Fundacio Barcelonabeta Brain Research Center; • SYNAPSE Research Management Partners; • Alzheimer Europe; • Alzheimer’s Disease International; • Universita Degli Studi Di Perugia; • Gates Ventures; • Davos Alzheimer’s Collaborative; • Combinostics; • Fujirebio; • Sanofi • C2N Diagnostics; • Neotiv; • Cambridge Cognition; • University of Leicester; •Imperial College of Science Technology and Medicine; • NICE I National Institute for Health and Care Excellence.


© 2024  THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

    •

  • Contenuto

    •

Vol 11 - N° 2

P. 329-338 - Marzo 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Findings from a Longitudinal Cohort Analysis
  • J. Chandler, M. Georgieva, Urvi Desai, N. Done, A. Gomez-Lievano, W. Ye, A. Zhao, D. Eid, A. Hilts, N. Kirson, T. Schilling
| Articolo seguente Articolo seguente
  • Exploring the Association between Amyloid-β and Memory Markers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults
  • Mario A. Parra, Y. Gazes, C. Habeck, Y. Stern

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account

Aide & support

Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.

Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.